Science Explorer Back to mapMap
Discussion
Institution · Vion Pharmaceuticals (United States)

Most cited papers from Vion Pharmaceuticals (United States)

Vion Pharmaceuticals (United States)

What are the most cited papers from Vion Pharmaceuticals (United States)?

The most cited paper from Vion Pharmaceuticals (United States) is "Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma" (John F. Toso, 2002), with 631 citations. Next come "Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo" (479) and "Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective" (390).

Showing 50 of 60 papers. Every paper with more than 79 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma John F. Toso · Journal of Clinical Oncology Open access 2002 631
2 Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo K. Brooks Low, Martina Ittensohn, Trung Bao Le et al. · Nature Biotechnology 1999 479
3 Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective Mohamad Shebley et al. · Clinical Pharmacology & Therapeutics Open access 10 Jan 2018 390
4 Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain of Salmonella typhimurium Caroline Clairmont, K. C. Lee, Jeremy Andrew Pike et al. · The Journal of Infectious Diseases Jun 2000 359
5 Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study Antony D Loebel, Josephine B. Cucchiaro, Robert Silva et al. · American Journal of Psychiatry 30 Oct 2013 344
6 Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients John J. Nemunaitis, Casey C. Cunningham, Neil N. Senzer et al. · Cancer Gene Therapy 22 Sep 2003 344
7 Seizure diaries for clinical research and practice: Limitations and future prospects Robert S. Fisher, David E. Blum, Bree D. DiVentura et al. · Epilepsy & Behavior 30 May 2012 314
8 A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia Kenneth S. Koblan, JUSTINE M. KENT, Seth C. Hopkins et al. · New England Journal of Medicine 15 Apr 2020 297
9 Lurasidone as Adjunctive Therapy With Lithium or Valproate for the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study Antony D Loebel, Josephine B. Cucchiaro, Robert Silva et al. · American Journal of Psychiatry 30 Oct 2013 295
10 Bacteria as tumour-targeting vectors John M. Pawelek, K. Brooks Low, David G. Bermudes · The Lancet Oncology Sep 2003 290
11 A Review of In Vitro Drug Release Test Methods for Nano-Sized Dosage Forms Susan S. D’Souza · Advances in Pharmaceutics Open access 20 Nov 2014 264
12 Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis Thomas J. Struble et al. · Journal of Medicinal Chemistry Open access 3 Apr 2020 263
13 Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study Herbert Y. Meltzer, Josephine B. Cucchiaro, Robert Silva et al. · American Journal of Psychiatry 16 Jun 2011 252
14 Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. Christine Stowe Rinder, Henry M. Rinder, Brian R. Smith et al. · Journal of Clinical Investigation Open access Sep 1995 214
15 The Economic Burden of Schizophrenia in the United States Aditi P. Kadakia, Maryaline Catillon, Qi Fan et al. · The Journal of Clinical Psychiatry Open access 6 Oct 2022 208
16 Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability Alaa-Eldin F. Nassar, Amin M. Kamel, Caroline Clarimont · Drug Discovery Today Dec 2004 207
17 Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis Michael Joshua Ostacher, Daisy Ng‐Mak, Pankaj Patel et al. · The World Journal of Biological Psychiatry ReviewOpen access 7 Mar 2017 202
18 Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis Celso Arango, Daisy Ng‐Mak, Elaine Finn et al. · European Child & Adolescent Psychiatry ReviewOpen access 22 Nov 2019 199
19 Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients Linda N. Abetz, Krithika Rajagopalan, Polyxane Mertzanis et al. · Health and Quality of Life Outcomes Open access 2011 180
20 SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action Nina Dedic, PHILIP G. JONES, Seth C. Hopkins et al. · Journal of Pharmacology and Experimental Therapeutics Open access Aug 2019 178
21 Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation Douglas H. Thamm, Ilene D. Kurzman, Ivan King et al. · Clinical Cancer Research Jul 2005 175
22 Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial Antony D Loebel, Josephine B. Cucchiaro, Kaushik Sarma et al. · Schizophrenia Research Open access 14 Feb 2013 173
23 Use of preferentially replicating bacteria for the treatment of cancer Mario Sznol, Stanley Li Lin, David G. Bermudes et al. · Journal of Clinical Investigation Open access 15 Apr 2000 171
24 Transforming Growth Factor β Blocks Tec Kinase Phosphorylation, Ca2+ Influx, and NFATc Translocation Causing Inhibition of T Cell Differentiation Chang-Hung Chen, Carole Seguin‐Devaux, Nancy A. Burke et al. · The Journal of Experimental Medicine Open access 16 Jun 2003 170
25 POSIT: Flexible Shape-Guided Docking For Pose Prediction Brian Kelley, Scott P. Brown, Gregory L. Warren et al. · Journal of Chemical Information and Modeling Open access 7 Jul 2015 166
26 Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models Bohdana Ratitch, Michael O’Kelly, Robert L. Tosiello · Pharmaceutical Statistics 4 Jan 2013 156
27 Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks Kristian Reich, Richard Bruce Warren, Lars Iversen et al. · British Journal of Dermatology Open access 20 Jun 2019 148
28 Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study Henry A. Nasrallah, Robert Silva, Debra L. Phillips et al. · Journal of Psychiatric Research 18 Feb 2013 148
29 Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion Scott Wadler, Della Makower, Caroline Clairmont et al. · Journal of Clinical Oncology 29 Apr 2004 146
30 Clinical Evaluation of Glimepiride versus Glyburide in NIDDM in a Double-Blind Comparative Study Diana G. Dills, Jill Schneider · Hormone and Metabolic Research Open access Sep 1996 134
31 Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study Melissa P. DelBello, ROBERT S. GOLDMAN, Debra L. Phillips et al. · Journal of the American Academy of Child & Adolescent Psychiatry Open access 14 Oct 2017 133
32 Tumor-Targeted Salmonella Expressing Cytosine Deaminase as an Anticancer Agent Ivan King, David G. Bermudes, Stanley Li Lin et al. · Human Gene Therapy Jul 2002 125
33 Long-term safety and tolerability of lurasidone in schizophrenia Leslie Citrome, Josephine B. Cucchiaro, Kaushik Sarma et al. · International Clinical Psychopharmacology 6 Mar 2012 122
34 Antitumor Effect of VNP20009, an Attenuated Salmonella , in Murine Tumor Models Xiaobo Luo, Zeying Li, Stanley Li Lin et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics Open access Nov 2001 119
35 Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study Antony D Loebel, Josephine B. Cucchiaro, Jane Xu et al. · Schizophrenia Research Open access 17 Apr 2013 118
36 Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule Lynn G. Feun, Manuel Modiano, King Lee et al. · Cancer Chemotherapy and Pharmacology Sep 2002 118
37 Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study Masaaki Ogasa, Tatsuya Kimura, Mitsutaka Nakamura et al. · Psychopharmacology Open access 18 Aug 2012 116
38 Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial‐onset seizures: Results of a phase III , double‐blind, randomized, placebo‐controlled trial Michael R. Sperling, Bassel W Abou-Khalil, Jay H. Harvey et al. · Epilepsia Open access 22 Dec 2014 114
39 Lurasidone for the Treatment of Irritability Associated with Autistic Disorder Antony D Loebel, Matthew N. Brams, ROBERT S. GOLDMAN et al. · Journal of Autism and Developmental Disorders Open access 11 Dec 2015 111
40 Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. John R. Murren, Manuel Modiano, Caroline Clairmont et al. · PubMed 15 Sep 2003 108
41 Pharmacological activation and inhibition of Slack (Slo2.2) channels Bingwei V. Yang, Valentin K. Gribkoff, Jianbin Pan et al. · Neuropharmacology 30 Jul 2006 106
42 Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine Michelle Kokkinou, Elaine E. Irvine, David R. Bonsall et al. · Molecular Psychiatry Open access 7 May 2020 105
43 SptP, a Salmonella typhimurium type III-secreted protein, inhibits the mitogen-activated protein kinase pathway by inhibiting Raf activation Stanley Li Lin, Trung X. Le, Daniel S. Cowen · Cellular Microbiology Open access Apr 2003 102
44 Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies Nina Dedic, Heather Dworak, Courtney M. Zeni et al. · International Journal of Molecular Sciences Open access 7 Dec 2021 100
45 Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation Gulshan Sharma, Donald A. Mahler, Valerie M. Mayorga et al. · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation Open access 2017 100
46 A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders Judith E. Karp, Francis Joseph Giles, Ivana Gojo et al. · Leukemia Research Open access 21 Jul 2007 99
47 Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone Philip D. Harvey, Masaaki Ogasa, Josephine B. Cucchiaro et al. · Schizophrenia Research Feb 2011 95
48 Construction of VNP20009: A Novel, Genetically Stable Antibiotic-Sensitive Strain of Tumor-Targeting Salmonella for Parenteral Administration in Humans K. Brooks Low, Martina Ittensohn, Xiang Luo et al. · Humana Press eBooks Book chapter 17 Feb 2004 95
49 Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia Francis Joseph Giles, Paula M. Fracasso, Hagop M. Kantarjian et al. · Leukemia Research 21 Jun 2003 93
50 Attenuated Salmonella Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy Frank Friedlos, Panos Lehouritis, Lesley M. Ogilvie et al. · Clinical Cancer Research Jul 2008 91

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.